On 8 November 2024, Korea Biomedical Review reported that Alteogen has signed an exclusive licence agreement with Daiichi Sankyo for the development and commercialisation of a subcutaneous (SC) injection form of Enhertu® (trastuzumab deruxtecan). The agreement includes an upfront payment of US$20 million from Daiichi Sankyo to Alteogen, with further payments of up to US$280 million subject to achievement of regulatory approvals and sales milestones, and additional royalties. According to Alteogen, the total potential revenue from the deal could reach US$300 million.
Alteogen will be responsible for producing its human hyaluronidase technology (ALT-B4) to create the SC formulation.
Enhertu® is the subject of a collaboration between AstraZeneca and Daiichi Sankyo entered in March 2019, under which the companies jointly develop and commercialise trastuzumab deruxtecan globally, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is solely responsible for manufacturing and supply.